| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 03/31/2004 | EP1403381A1 Improved method for detecting and identifying microorganism causative of infection |
| 03/31/2004 | EP1403379A1 Enhanced coamplification of nucleic acids |
| 03/31/2004 | EP1403377A1 Consensus phytases |
| 03/31/2004 | EP1403376A2 Expression of heterologous genes according to a targeted expression profile |
| 03/31/2004 | EP1403375A2 Recombinant live avian vaccin, using avian herpes virus as vector |
| 03/31/2004 | EP1403374A1 Gene transfer into primate emborynic stem cells using vsv-g-pseudotype simian immunodeficiency virus vector |
| 03/31/2004 | EP1403373A1 Saponin-digesting enzymes, genes thereof and soyasapogenol b mass production system |
| 03/31/2004 | EP1403372A2 Composition and methods for the treatment and diagnosis of cardiovascular disease |
| 03/31/2004 | EP1403371A1 Novel polypeptide and use thereof |
| 03/31/2004 | EP1403370A1 Polynucleotide probe and primer for detecting beer-clouding lactic acid bacteria and method of detecting beer-clouding lactic acid bacteria |
| 03/31/2004 | EP1403367A1 Method of testing drug for treating or preventing diseases such as hyperlipemia |
| 03/31/2004 | EP1403364A1 Mutant rna polymerases |
| 03/31/2004 | EP1403285A1 Fibroblast growth factor receptors |
| 03/31/2004 | EP1403284A1 HAb18G/CD147, IT'S AGONIST AND APPLICATION |
| 03/31/2004 | EP1403283A1 Tumor antigen |
| 03/31/2004 | EP1403281A1 Novel ligand and dna thereof |
| 03/31/2004 | EP1402953A1 Method for producing a microarray |
| 03/31/2004 | EP1402903A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
| 03/31/2004 | EP1402902A1 Method for treatment of vascular regeneration |
| 03/31/2004 | EP1402897A2 Novel indications of Mannan-binding lectin (MBL) in the treatment of immunocompromised individuals |
| 03/31/2004 | EP1402456A1 Methods for predicting the activities of cellular constituents |
| 03/31/2004 | EP1402262A2 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402261A1 Colon cancer antigen panel |
| 03/31/2004 | EP1402260A2 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders |
| 03/31/2004 | EP1402256A2 P-cadherin as a target for anti-cancer therapy |
| 03/31/2004 | EP1402254A1 Method and apparatus for high-speed approximate sub-string searches |
| 03/31/2004 | EP1402245A1 Methods and apparatus for characterization of single polymers |
| 03/31/2004 | EP1402076A2 Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays |
| 03/31/2004 | EP1402074A2 Methods and compositions using genetic package display |
| 03/31/2004 | EP1402073A1 Methods and compositions for assessment of pulmonary function and disorders |
| 03/31/2004 | EP1402072A1 Accurate and efficient quantification of dna sensitivity by real-time pcr |
| 03/31/2004 | EP1402071A2 Methods and products for analyzing nucleic acids based on methylation status |
| 03/31/2004 | EP1402070A2 Methods for the diagnosis of cancer based on the obcam and ntm genes |
| 03/31/2004 | EP1402069A1 Methods and products for analyzing nucleic acids using nick translation |
| 03/31/2004 | EP1402068A2 Evaluation of ultraviolet radiation damage to skin using new genemarkers, methods and compositions related thereto |
| 03/31/2004 | EP1402067A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402066A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 03/31/2004 | EP1402064A2 Protein arrays and methods and systems for producing the same |
| 03/31/2004 | EP1402063A1 Antisense modulation of phospholipase a2, group iia (synovial) expression |
| 03/31/2004 | EP1402058A2 Dgks as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1402054A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 03/31/2004 | EP1402053A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402051A2 Lces as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1402050A2 Methods for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gp41 fragments |
| 03/31/2004 | EP1402049A2 Production of high levels of transgenic factor viii with engineered stability, and its therapeutic uses |
| 03/31/2004 | EP1402048A2 Methods of 6-o-sulfating polysaccharides and 6-o-sulfated polysaccharide preparations |
| 03/31/2004 | EP1402047A1 Process for the fermentative preparation of d-pantothenic acid and/or salts thereof |
| 03/31/2004 | EP1402046A1 Process for the fermentative preparation of d-pantothenic acid and/or salts thereof |
| 03/31/2004 | EP1402043A1 Methods of administering vectors to synaptically connected neurons |
| 03/31/2004 | EP1402042A2 Abiotic stress responsive polynucleotides and polypeptides |
| 03/31/2004 | EP1402041A2 Use of fkbp chaperones as expression tool |
| 03/31/2004 | EP1402040A2 A novel intein and uses thereof |
| 03/31/2004 | EP1402039A1 MUTANT FORMS OF EtxB AND CtxB AND THEIR USE AS CARRIERS |
| 03/31/2004 | EP1402038A2 Identification and characterization of plant genes |
| 03/31/2004 | EP1402037A1 Plant genes involved in defense against pathogens |
| 03/31/2004 | EP1402036A2 Expression vectors encoding bacteriophage signal peptides |
| 03/31/2004 | EP1402035A2 G-protein coupled receptors and dna sequences thereof |
| 03/31/2004 | EP1402034A2 Identification of ses-1 and the uses of the same |
| 03/31/2004 | EP1402033A2 Novel endothelially expressed dnas and proteins, and their use |
| 03/31/2004 | EP1402032A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis |
| 03/31/2004 | EP1402031A2 Atopy |
| 03/31/2004 | EP1402030A2 43238, a g protein-coupled receptor and uses therefor |
| 03/31/2004 | EP1402029A2 Use of inhibitors of expression or activity of p8/com1 for treating tumors |
| 03/31/2004 | EP1402028A2 Oligonucleotides for regulating the gene coding for tnf-alpha and/or genes controlled thereby and use thereof |
| 03/31/2004 | EP1402026A2 39228, a human alcohol dehydrogenase and uses therefor |
| 03/31/2004 | EP1402025A1 Chimaeric phages |
| 03/31/2004 | EP1402024A2 Templated molecules and methods for using such molecules |
| 03/31/2004 | EP1402023A2 Method for generating replication defective viral vectors that are helper free |
| 03/31/2004 | EP1402022A2 Use of a tyrosine recombinase for genetic engineering |
| 03/31/2004 | EP1402021A1 A gene and uses therefor |
| 03/31/2004 | EP1402020A2 Methods, vectors, cell lines and kits for selecting nucleic acids having a desired feature |
| 03/31/2004 | EP1402019A1 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes |
| 03/31/2004 | EP1402018A1 Unigene unidirectional antisense library |
| 03/31/2004 | EP1402017A1 Random gene unidirectional antisense library |
| 03/31/2004 | EP1402015A2 A soluble complex comprising a retroviral surface glycoprotein |
| 03/31/2004 | EP1402013A2 Homoaconitase as a target for fungicides |
| 03/31/2004 | EP1402011A2 Proteins in a porous support |
| 03/31/2004 | EP1402010A2 8843, a human dual specificity phosphatase family member and uses therefor |
| 03/31/2004 | EP1402009A1 Novel mixed lineage kinase (7) (mlk7) polypeptide, polynucleotides encoding the same, and methods of use thereof |
| 03/31/2004 | EP1402007A1 Bcl-2 dnazymes |
| 03/31/2004 | EP1402006A1 Compositions and methods for high-level, large-scale production of recombinant proteins |
| 03/31/2004 | EP1402004A2 Remodeling of somatic nuclei upon addition of pluripotent cell extracts |
| 03/31/2004 | EP1402000A2 Structural and cytoskeleton-associated proteins |
| 03/31/2004 | EP1401999A2 B7 related protein-2 molecules and uses thereof |
| 03/31/2004 | EP1401962A1 Method for increasing hydrophilicity of fluorescent label compounds |
| 03/31/2004 | EP1401918A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/31/2004 | EP1401871A1 Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells |
| 03/31/2004 | EP1401870A2 Antibodies against tumor necrosis factor delta (april) |
| 03/31/2004 | EP1401869A1 Molecules and methods for inhibiting shedding of kim-1 |
| 03/31/2004 | EP1401867A2 Mycobacterial antigens expressed under low oxygen tension |
| 03/31/2004 | EP1401866A2 Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
| 03/31/2004 | EP1401865A2 Pathogenic and commensal vaccine antigens |
| 03/31/2004 | EP1401861A2 Cads as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1401859A2 Chimeric flavivirus vectors |
| 03/31/2004 | EP1401857A2 Purification of human serum albumin |
| 03/31/2004 | EP1401855A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 03/31/2004 | EP1401853A1 Modulators of pharmacological agents |
| 03/31/2004 | EP1401850A1 Nucleoside derivatives for library preparation |
| 03/31/2004 | EP1401849A1 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
| 03/31/2004 | EP1401776A1 A process for biochemical treatment of waste water using nano materials |